EE476 Cost-Minimization and Budget Impact Analysis of Abiraterone (Tarosyn® and Avitosyn®) as Second Line Treatment for Metastatic Prostate Cancer Resistant to Castration in Mexico
Abstract
Authors
C Dominguez P Sanchez I Monteon I Mercado Paladio Hernández JÁ